| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesenchymal Stem Cells | 24 | 2022 | 183 | 5.470 |
Why?
|
| Hematopoietic Stem Cells | 40 | 2020 | 104 | 4.750 |
Why?
|
| Hemophilia A | 8 | 2023 | 26 | 4.090 |
Why?
|
| Sheep | 58 | 2023 | 233 | 3.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 30 | 2016 | 118 | 2.850 |
Why?
|
| Bone Marrow Cells | 23 | 2022 | 125 | 2.580 |
Why?
|
| Fetal Blood | 13 | 2018 | 38 | 2.030 |
Why?
|
| Factor VIII | 8 | 2023 | 25 | 1.800 |
Why?
|
| Cell Differentiation | 32 | 2019 | 485 | 1.790 |
Why?
|
| Fetus | 26 | 2023 | 91 | 1.680 |
Why?
|
| Transplantation, Heterologous | 30 | 2015 | 123 | 1.670 |
Why?
|
| Antigens, CD34 | 26 | 2019 | 61 | 1.600 |
Why?
|
| Stem Cells | 11 | 2018 | 331 | 1.470 |
Why?
|
| Genetic Vectors | 14 | 2022 | 127 | 1.410 |
Why?
|
| Graft Survival | 13 | 2016 | 315 | 1.400 |
Why?
|
| Animals | 76 | 2023 | 8579 | 1.400 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 10 | 2018 | 83 | 1.320 |
Why?
|
| Stem Cell Niche | 4 | 2019 | 27 | 1.180 |
Why?
|
| Cytomegalovirus | 8 | 2014 | 31 | 1.170 |
Why?
|
| Endothelial Cells | 5 | 2022 | 204 | 1.170 |
Why?
|
| Models, Animal | 9 | 2014 | 198 | 1.140 |
Why?
|
| Pregnancy | 22 | 2023 | 1069 | 1.130 |
Why?
|
| Stromal Cells | 10 | 2008 | 86 | 1.130 |
Why?
|
| Bone Marrow | 8 | 2022 | 77 | 1.120 |
Why?
|
| Humans | 97 | 2023 | 34562 | 1.110 |
Why?
|
| Hematopoiesis | 12 | 2018 | 33 | 1.040 |
Why?
|
| Bone Marrow Transplantation | 8 | 2016 | 70 | 1.000 |
Why?
|
| Stem Cell Transplantation | 8 | 2020 | 229 | 0.990 |
Why?
|
| Regenerative Medicine | 4 | 2022 | 219 | 0.880 |
Why?
|
| Dependovirus | 2 | 2022 | 20 | 0.850 |
Why?
|
| Cytomegalovirus Infections | 6 | 2014 | 49 | 0.850 |
Why?
|
| Cosmic Radiation | 3 | 2018 | 13 | 0.820 |
Why?
|
| Cell Proliferation | 14 | 2019 | 633 | 0.790 |
Why?
|
| Transplantation Chimera | 9 | 2007 | 22 | 0.780 |
Why?
|
| Viral Proteins | 2 | 2013 | 35 | 0.750 |
Why?
|
| Cell Communication | 3 | 2019 | 42 | 0.690 |
Why?
|
| Hemophilia B | 1 | 2021 | 6 | 0.690 |
Why?
|
| Cells, Cultured | 22 | 2020 | 889 | 0.690 |
Why?
|
| Cell Culture Techniques | 11 | 2018 | 177 | 0.670 |
Why?
|
| Liver | 11 | 2014 | 513 | 0.610 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2019 | 30 | 0.600 |
Why?
|
| Fetal Therapies | 1 | 2019 | 2 | 0.590 |
Why?
|
| Liver Regeneration | 2 | 2010 | 25 | 0.590 |
Why?
|
| Hepatocytes | 5 | 2010 | 84 | 0.570 |
Why?
|
| Cell Movement | 6 | 2012 | 182 | 0.570 |
Why?
|
| Membrane Proteins | 7 | 2013 | 268 | 0.560 |
Why?
|
| Female | 35 | 2023 | 21532 | 0.560 |
Why?
|
| Coculture Techniques | 8 | 2019 | 87 | 0.530 |
Why?
|
| Models, Biological | 6 | 2018 | 432 | 0.510 |
Why?
|
| Gene Transfer Techniques | 6 | 2022 | 66 | 0.510 |
Why?
|
| Blood Coagulation | 2 | 2023 | 20 | 0.510 |
Why?
|
| Blood Transfusion, Intrauterine | 2 | 2016 | 4 | 0.500 |
Why?
|
| Occupational Exposure | 2 | 2016 | 237 | 0.490 |
Why?
|
| Cell Division | 8 | 2005 | 99 | 0.490 |
Why?
|
| Killer Cells, Natural | 5 | 2012 | 28 | 0.480 |
Why?
|
| RNA-Binding Proteins | 2 | 2013 | 70 | 0.470 |
Why?
|
| Intestines | 2 | 2013 | 66 | 0.460 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 25 | 0.460 |
Why?
|
| Genetic Engineering | 2 | 2012 | 23 | 0.450 |
Why?
|
| DNA, Viral | 3 | 2014 | 57 | 0.450 |
Why?
|
| Phenotype | 12 | 2019 | 657 | 0.440 |
Why?
|
| Culture Media, Serum-Free | 4 | 2008 | 16 | 0.430 |
Why?
|
| Immunomodulation | 2 | 2013 | 32 | 0.420 |
Why?
|
| Postural Balance | 1 | 2016 | 152 | 0.420 |
Why?
|
| Placenta | 3 | 2023 | 76 | 0.420 |
Why?
|
| Hemarthrosis | 2 | 2011 | 4 | 0.400 |
Why?
|
| Dendritic Cells | 2 | 2018 | 63 | 0.400 |
Why?
|
| Pesticides | 1 | 2016 | 201 | 0.400 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2013 | 30 | 0.390 |
Why?
|
| Viral Envelope Proteins | 1 | 2013 | 12 | 0.390 |
Why?
|
| Immediate-Early Proteins | 1 | 2013 | 10 | 0.390 |
Why?
|
| Prenatal Diagnosis | 3 | 2023 | 26 | 0.390 |
Why?
|
| Complement System Proteins | 1 | 2013 | 9 | 0.390 |
Why?
|
| Receptor, EphB2 | 1 | 2013 | 4 | 0.390 |
Why?
|
| Transduction, Genetic | 5 | 2013 | 46 | 0.390 |
Why?
|
| Flow Cytometry | 17 | 2011 | 198 | 0.390 |
Why?
|
| Glycoproteins | 1 | 2013 | 44 | 0.390 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 248 | 0.380 |
Why?
|
| Transients and Migrants | 1 | 2016 | 304 | 0.380 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 75 | 0.370 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2020 | 13 | 0.360 |
Why?
|
| Retroviridae | 9 | 2012 | 28 | 0.360 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 1129 | 0.340 |
Why?
|
| Prenatal Care | 3 | 2022 | 55 | 0.340 |
Why?
|
| Therapeutics | 1 | 2010 | 2 | 0.330 |
Why?
|
| Cell Lineage | 8 | 2013 | 71 | 0.320 |
Why?
|
| Gestational Age | 6 | 2014 | 134 | 0.320 |
Why?
|
| Mice | 18 | 2019 | 2720 | 0.320 |
Why?
|
| Adult | 13 | 2023 | 10030 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2007 | 8 | 0.310 |
Why?
|
| Hispanic Americans | 1 | 2016 | 948 | 0.310 |
Why?
|
| Liver Diseases | 1 | 2010 | 76 | 0.310 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 112 | 0.300 |
Why?
|
| Immune Tolerance | 4 | 2015 | 71 | 0.300 |
Why?
|
| RNA, Messenger | 8 | 2013 | 545 | 0.290 |
Why?
|
| Docosahexaenoic Acids | 1 | 2009 | 25 | 0.290 |
Why?
|
| Apoptosis | 3 | 2016 | 400 | 0.290 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2008 | 8 | 0.290 |
Why?
|
| Antigens, CD | 10 | 2008 | 106 | 0.280 |
Why?
|
| Recombinant Proteins | 6 | 2020 | 281 | 0.280 |
Why?
|
| Cell Line | 8 | 2019 | 476 | 0.270 |
Why?
|
| Time Factors | 10 | 2010 | 2353 | 0.260 |
Why?
|
| Immunophenotyping | 11 | 2009 | 51 | 0.260 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 215 | 0.250 |
Why?
|
| Transplantation, Homologous | 5 | 2016 | 165 | 0.250 |
Why?
|
| Endothelium, Vascular | 3 | 1997 | 163 | 0.240 |
Why?
|
| Gene Expression | 4 | 2016 | 363 | 0.240 |
Why?
|
| Pancytopenia | 2 | 1996 | 5 | 0.230 |
Why?
|
| Fluorescent Dyes | 2 | 2019 | 55 | 0.220 |
Why?
|
| Sheep, Domestic | 2 | 2016 | 19 | 0.220 |
Why?
|
| Stem Cell Factor | 6 | 2010 | 13 | 0.210 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 781 | 0.210 |
Why?
|
| Cell Separation | 4 | 2009 | 93 | 0.210 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2007 | 29 | 0.200 |
Why?
|
| Male | 13 | 2022 | 20740 | 0.200 |
Why?
|
| Neoplasms | 1 | 2010 | 793 | 0.190 |
Why?
|
| Uterus | 2 | 2019 | 106 | 0.190 |
Why?
|
| Mesoderm | 1 | 2002 | 13 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 7 | 2014 | 204 | 0.190 |
Why?
|
| Tissue Distribution | 2 | 2013 | 74 | 0.180 |
Why?
|
| Transgenes | 5 | 2008 | 52 | 0.180 |
Why?
|
| Organoids | 1 | 2022 | 99 | 0.170 |
Why?
|
| Factor IX | 1 | 2021 | 11 | 0.170 |
Why?
|
| Neurons | 1 | 2005 | 491 | 0.170 |
Why?
|
| DNA Damage | 2 | 2018 | 97 | 0.170 |
Why?
|
| Chimera | 4 | 1998 | 10 | 0.170 |
Why?
|
| Injections, Intraperitoneal | 3 | 2011 | 51 | 0.160 |
Why?
|
| Interleukin-6 | 4 | 2012 | 258 | 0.160 |
Why?
|
| Kidney | 2 | 2010 | 528 | 0.160 |
Why?
|
| Erythropoiesis | 1 | 2020 | 7 | 0.160 |
Why?
|
| Multipotent Stem Cells | 1 | 2020 | 17 | 0.160 |
Why?
|
| Microtechnology | 1 | 2019 | 4 | 0.150 |
Why?
|
| Anemia | 1 | 2020 | 58 | 0.150 |
Why?
|
| Radiation Injuries | 2 | 2019 | 87 | 0.150 |
Why?
|
| Kinetics | 4 | 2009 | 259 | 0.150 |
Why?
|
| Islets of Langerhans | 2 | 2010 | 79 | 0.150 |
Why?
|
| Antigens, CD7 | 2 | 2010 | 4 | 0.150 |
Why?
|
| Consensus | 1 | 2019 | 92 | 0.140 |
Why?
|
| Weightlessness | 1 | 2018 | 10 | 0.140 |
Why?
|
| Solar Energy | 1 | 2018 | 4 | 0.140 |
Why?
|
| Bystander Effect | 1 | 2018 | 6 | 0.140 |
Why?
|
| Protons | 1 | 2018 | 23 | 0.140 |
Why?
|
| Fetal Tissue Transplantation | 3 | 2005 | 5 | 0.140 |
Why?
|
| Ferrets | 1 | 2018 | 21 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2018 | 84 | 0.130 |
Why?
|
| Interleukin-8 | 1 | 1997 | 27 | 0.130 |
Why?
|
| Indocyanine Green | 1 | 2018 | 14 | 0.130 |
Why?
|
| Biocompatible Materials | 2 | 2010 | 242 | 0.130 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 54 | 0.130 |
Why?
|
| Membrane Glycoproteins | 3 | 2009 | 118 | 0.130 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 66 | 0.130 |
Why?
|
| Iron | 1 | 2018 | 121 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2011 | 730 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2018 | 58 | 0.130 |
Why?
|
| Splenomegaly | 1 | 2016 | 7 | 0.130 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 9 | 0.130 |
Why?
|
| Regeneration | 1 | 2018 | 179 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 302 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2012 | 281 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 135 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 25 | 0.120 |
Why?
|
| Chemokine CXCL12 | 1 | 2016 | 29 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 248 | 0.120 |
Why?
|
| Osteoblasts | 2 | 2014 | 44 | 0.120 |
Why?
|
| Base Sequence | 3 | 2012 | 265 | 0.120 |
Why?
|
| Colony-Forming Units Assay | 7 | 2010 | 18 | 0.120 |
Why?
|
| Microscopy, Confocal | 2 | 2013 | 80 | 0.110 |
Why?
|
| Purkinje Fibers | 2 | 2006 | 3 | 0.110 |
Why?
|
| North Carolina | 2 | 2020 | 1613 | 0.110 |
Why?
|
| Fetal Diseases | 3 | 2004 | 19 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 49 | 0.110 |
Why?
|
| Electromagnetic Fields | 1 | 2015 | 30 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 130 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2008 | 271 | 0.110 |
Why?
|
| Transplantation, Autologous | 3 | 2015 | 104 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 19 | 0.110 |
Why?
|
| Amniotic Fluid | 1 | 2015 | 86 | 0.110 |
Why?
|
| beta-Galactosidase | 4 | 2002 | 20 | 0.110 |
Why?
|
| Fetal Development | 1 | 2014 | 27 | 0.100 |
Why?
|
| Cytokines | 2 | 2018 | 269 | 0.100 |
Why?
|
| Virus Replication | 1 | 2014 | 43 | 0.100 |
Why?
|
| Kanamycin Kinase | 2 | 2012 | 6 | 0.100 |
Why?
|
| Lung | 2 | 2014 | 279 | 0.100 |
Why?
|
| Muscle, Smooth | 2 | 2006 | 152 | 0.100 |
Why?
|
| Immune Evasion | 1 | 2013 | 2 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 15 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2016 | 926 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2003 | 10 | 0.100 |
Why?
|
| Secretory Vesicles | 1 | 2013 | 4 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 18 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 70 | 0.100 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 389 | 0.100 |
Why?
|
| Virus Latency | 1 | 2012 | 7 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2012 | 22 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 72 | 0.100 |
Why?
|
| Intestine, Small | 1 | 2013 | 45 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 165 | 0.090 |
Why?
|
| Growth Substances | 2 | 2006 | 10 | 0.090 |
Why?
|
| Transfection | 3 | 2005 | 216 | 0.090 |
Why?
|
| Tissue Engineering | 2 | 2010 | 700 | 0.090 |
Why?
|
| Embryo, Mammalian | 2 | 2004 | 35 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 341 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 91 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2012 | 122 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 38 | 0.090 |
Why?
|
| Age Factors | 3 | 2011 | 1262 | 0.090 |
Why?
|
| Receptors, Virus | 1 | 2012 | 15 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2012 | 43 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2012 | 145 | 0.090 |
Why?
|
| Isoantibodies | 1 | 2011 | 13 | 0.090 |
Why?
|
| Sus scrofa | 1 | 2011 | 49 | 0.090 |
Why?
|
| Remission Induction | 1 | 2011 | 97 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2019 | 771 | 0.090 |
Why?
|
| Species Specificity | 2 | 2009 | 101 | 0.090 |
Why?
|
| Myoblasts, Cardiac | 1 | 2011 | 1 | 0.080 |
Why?
|
| Insulin | 2 | 2010 | 394 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2011 | 109 | 0.080 |
Why?
|
| Cell Survival | 2 | 2009 | 304 | 0.080 |
Why?
|
| Virus Integration | 1 | 2010 | 5 | 0.080 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 38 | 0.080 |
Why?
|
| Genes | 1 | 2010 | 15 | 0.080 |
Why?
|
| Cell Adhesion | 4 | 2010 | 116 | 0.080 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 31 | 0.080 |
Why?
|
| HIV-1 | 1 | 2010 | 46 | 0.080 |
Why?
|
| Middle Aged | 4 | 2020 | 12726 | 0.080 |
Why?
|
| Umbilical Veins | 3 | 2004 | 15 | 0.080 |
Why?
|
| Immunosuppression | 1 | 2010 | 120 | 0.080 |
Why?
|
| Coagulants | 1 | 2009 | 3 | 0.080 |
Why?
|
| Partial Thromboplastin Time | 1 | 2009 | 7 | 0.080 |
Why?
|
| Codon, Nonsense | 1 | 2009 | 6 | 0.080 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2009 | 6 | 0.080 |
Why?
|
| Embryonic Stem Cells | 1 | 2010 | 28 | 0.080 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2008 | 7 | 0.080 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 2 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 71 | 0.080 |
Why?
|
| Immunoassay | 1 | 2009 | 16 | 0.080 |
Why?
|
| Exons | 1 | 2009 | 53 | 0.080 |
Why?
|
| Antigens, Surface | 2 | 2001 | 26 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2009 | 16 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1999 | 18 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 49 | 0.080 |
Why?
|
| Organic Chemicals | 1 | 2009 | 7 | 0.080 |
Why?
|
| Mitosis | 1 | 2009 | 26 | 0.080 |
Why?
|
| Thymus Gland | 4 | 2008 | 17 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2012 | 103 | 0.080 |
Why?
|
| Organ Specificity | 3 | 2005 | 86 | 0.080 |
Why?
|
| Interleukin-3 | 3 | 2003 | 13 | 0.070 |
Why?
|
| Annexin A5 | 1 | 2009 | 8 | 0.070 |
Why?
|
| DNA Fragmentation | 1 | 2009 | 9 | 0.070 |
Why?
|
| Germ Cells | 1 | 2009 | 12 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 16 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2009 | 43 | 0.070 |
Why?
|
| DNA | 3 | 2022 | 235 | 0.070 |
Why?
|
| Mice, Inbred NOD | 4 | 2015 | 27 | 0.070 |
Why?
|
| Vitronectin | 1 | 2008 | 6 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 111 | 0.070 |
Why?
|
| Cell Fusion | 1 | 2008 | 4 | 0.070 |
Why?
|
| Cell-Derived Microparticles | 1 | 2008 | 5 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2011 | 60 | 0.070 |
Why?
|
| Fibronectins | 1 | 2008 | 40 | 0.070 |
Why?
|
| Brain | 2 | 2014 | 1032 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2008 | 10 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3623 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 214 | 0.070 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2008 | 6 | 0.070 |
Why?
|
| Myocardium | 2 | 2006 | 199 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 21 | 0.070 |
Why?
|
| Clone Cells | 1 | 2007 | 37 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2005 | 73 | 0.070 |
Why?
|
| Culture Media, Conditioned | 2 | 2018 | 53 | 0.070 |
Why?
|
| Astronauts | 2 | 2018 | 12 | 0.070 |
Why?
|
| Injections | 1 | 2007 | 76 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 180 | 0.060 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 1997 | 5 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 755 | 0.060 |
Why?
|
| Aged | 2 | 2020 | 11022 | 0.060 |
Why?
|
| ADP-ribosyl Cyclase | 2 | 2004 | 4 | 0.060 |
Why?
|
| Mitochondria | 1 | 2008 | 219 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 849 | 0.060 |
Why?
|
| Coiled Bodies | 1 | 2006 | 2 | 0.060 |
Why?
|
| Gastroparesis | 1 | 2006 | 10 | 0.060 |
Why?
|
| Interleukin-1 | 2 | 1997 | 51 | 0.060 |
Why?
|
| Diabetic Neuropathies | 1 | 2006 | 29 | 0.060 |
Why?
|
| Proviruses | 1 | 2005 | 3 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 3 | 2018 | 99 | 0.060 |
Why?
|
| Surface Properties | 3 | 2010 | 38 | 0.060 |
Why?
|
| HLA-DR Antigens | 1 | 2005 | 8 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2005 | 27 | 0.060 |
Why?
|
| Mice, SCID | 3 | 2015 | 74 | 0.060 |
Why?
|
| Spermatozoa | 1 | 2005 | 30 | 0.060 |
Why?
|
| Heart | 1 | 2006 | 191 | 0.060 |
Why?
|
| Tissue Donors | 2 | 2004 | 208 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 48 | 0.050 |
Why?
|
| Transplantation | 1 | 2004 | 13 | 0.050 |
Why?
|
| Cell Count | 1 | 2004 | 55 | 0.050 |
Why?
|
| Fetal Heart | 1 | 2004 | 5 | 0.050 |
Why?
|
| Brain Tissue Transplantation | 1 | 2004 | 3 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2003 | 41 | 0.050 |
Why?
|
| Fluorescence | 2 | 2018 | 22 | 0.050 |
Why?
|
| Aging | 1 | 2009 | 1010 | 0.050 |
Why?
|
| Bioreactors | 1 | 2003 | 61 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 600 | 0.050 |
Why?
|
| Sequence Deletion | 2 | 2012 | 41 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 842 | 0.050 |
Why?
|
| Erythropoietin | 2 | 2020 | 33 | 0.050 |
Why?
|
| Parturition | 1 | 2022 | 11 | 0.050 |
Why?
|
| Bone and Bones | 2 | 2018 | 99 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 53 | 0.050 |
Why?
|
| DNA Primers | 2 | 2012 | 92 | 0.040 |
Why?
|
| Child | 2 | 2022 | 2614 | 0.040 |
Why?
|
| Antibody Specificity | 3 | 2008 | 20 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 118 | 0.040 |
Why?
|
| Photoelectron Spectroscopy | 2 | 2010 | 2 | 0.040 |
Why?
|
| Protein Binding | 2 | 2012 | 255 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 16 | 0.040 |
Why?
|
| Hematinics | 1 | 2020 | 6 | 0.040 |
Why?
|
| Gold | 2 | 2010 | 19 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 49 | 0.040 |
Why?
|
| Fetal Viability | 1 | 1999 | 2 | 0.040 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1999 | 3 | 0.040 |
Why?
|
| Macrophages | 2 | 2003 | 216 | 0.040 |
Why?
|
| Adsorption | 2 | 2010 | 6 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 1999 | 18 | 0.040 |
Why?
|
| Integrins | 1 | 1999 | 45 | 0.040 |
Why?
|
| Antibodies | 1 | 1999 | 59 | 0.040 |
Why?
|
| Neutrons | 1 | 2019 | 1 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2019 | 25 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 82 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 1999 | 143 | 0.040 |
Why?
|
| Plasmodium falciparum | 1 | 1998 | 5 | 0.040 |
Why?
|
| Endothelium | 1 | 1998 | 7 | 0.040 |
Why?
|
| Bleomycin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 380 | 0.040 |
Why?
|
| Erythrocytes | 1 | 1998 | 45 | 0.030 |
Why?
|
| Histones | 1 | 2018 | 53 | 0.030 |
Why?
|
| DNA Repair | 1 | 2018 | 57 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2018 | 128 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 60 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 291 | 0.030 |
Why?
|
| Muscles | 1 | 2018 | 69 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2018 | 19 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2018 | 23 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 80 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 328 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2011 | 24 | 0.030 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 19 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 1997 | 64 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 52 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 104 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1997 | 89 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 939 | 0.030 |
Why?
|
| Wound Healing | 1 | 2018 | 190 | 0.030 |
Why?
|
| Body Burden | 1 | 2016 | 7 | 0.030 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 1996 | 2 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1996 | 19 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 45 | 0.030 |
Why?
|
| Thrombopoietin | 2 | 2010 | 4 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 526 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 96 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 1996 | 8 | 0.030 |
Why?
|
| DNA Probes | 1 | 1996 | 20 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 136 | 0.030 |
Why?
|
| Immunomagnetic Separation | 2 | 2011 | 4 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2010 | 59 | 0.030 |
Why?
|
| Chondrogenesis | 1 | 2015 | 20 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2015 | 81 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2006 | 203 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1994 | 23 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 24 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2008 | 148 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 1994 | 54 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1994 | 23 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 2013 | 13 | 0.030 |
Why?
|
| Capsid | 1 | 2013 | 9 | 0.030 |
Why?
|
| Myocytes, Cardiac | 2 | 2004 | 97 | 0.030 |
Why?
|
| Epitopes | 1 | 2013 | 28 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 35 | 0.030 |
Why?
|
| United States | 1 | 2022 | 4278 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 88 | 0.030 |
Why?
|
| Rats | 2 | 2011 | 1946 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2003 | 6 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2012 | 11 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2012 | 12 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2012 | 35 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2012 | 18 | 0.020 |
Why?
|
| Thrombin | 1 | 2012 | 26 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2012 | 27 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2012 | 14 | 0.020 |
Why?
|
| Cricetinae | 1 | 2012 | 52 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 25 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 73 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 319 | 0.020 |
Why?
|
| Cell Transplantation | 2 | 2004 | 65 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 3825 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 2004 | 24 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 79 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Rats, Nude | 1 | 2011 | 48 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 34 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 55 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2010 | 26 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2002 | 19 | 0.020 |
Why?
|
| Interleukin-2 | 2 | 2002 | 40 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 67 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 142 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2010 | 35 | 0.020 |
Why?
|
| Suspensions | 1 | 2010 | 2 | 0.020 |
Why?
|
| Imidazoles | 1 | 2010 | 99 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 34 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2010 | 106 | 0.020 |
Why?
|
| Interleukin-7 | 2 | 2001 | 9 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 2009 | 6 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 264 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 13 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2011 | 192 | 0.020 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 12 | 0.020 |
Why?
|
| Lymphokines | 1 | 1999 | 18 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 60 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 1999 | 22 | 0.020 |
Why?
|
| Sertoli Cells | 1 | 2009 | 6 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 124 | 0.020 |
Why?
|
| Granulocytes | 2 | 2000 | 13 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 136 | 0.020 |
Why?
|
| Adhesiveness | 1 | 2008 | 2 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2008 | 3 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2008 | 5 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 1999 | 118 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 326 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2008 | 20 | 0.020 |
Why?
|
| Biological Assay | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cattle | 1 | 2008 | 118 | 0.020 |
Why?
|
| Autoantigens | 1 | 2008 | 16 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 36 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1123 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2010 | 529 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1355 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2006 | 12 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 87 | 0.010 |
Why?
|
| Testis | 1 | 2005 | 72 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2005 | 69 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2006 | 256 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 2004 | 35 | 0.010 |
Why?
|
| Albumins | 1 | 2004 | 47 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2004 | 113 | 0.010 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2004 | 6 | 0.010 |
Why?
|
| Femur | 1 | 2004 | 82 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 62 | 0.010 |
Why?
|
| Magnetics | 1 | 2003 | 5 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 44 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 21 | 0.010 |
Why?
|
| Adipocytes | 1 | 2004 | 85 | 0.010 |
Why?
|
| Biomimetics | 1 | 2003 | 7 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 157 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 58 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 3805 | 0.010 |
Why?
|
| Hippocampus | 1 | 2004 | 225 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 56 | 0.010 |
Why?
|
| Fetal Proteins | 1 | 2001 | 7 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 22 | 0.010 |
Why?
|
| Antigens | 1 | 2001 | 36 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 77 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 40 | 0.010 |
Why?
|
| Immunization | 1 | 2001 | 40 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2001 | 50 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 4137 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 44 | 0.010 |
Why?
|
| Integrin alpha4beta1 | 1 | 1999 | 4 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2000 | 69 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1999 | 17 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2001 | 274 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 18 | 0.010 |
Why?
|
| Karyotyping | 1 | 1998 | 29 | 0.010 |
Why?
|
| Granzymes | 1 | 1998 | 7 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1998 | 22 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1998 | 143 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 77 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1996 | 25 | 0.010 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1996 | 6 | 0.010 |
Why?
|
| X Chromosome | 1 | 1996 | 27 | 0.010 |
Why?
|
| Fathers | 1 | 1996 | 13 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1996 | 27 | 0.010 |
Why?
|